Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Read here for a detailed financial analysis of Medifast stock post-pandemic, GLP-1 impact, and the company's collaboration ...

A large new study has shed light on the wider health impacts of taking Ozempic-style drugs. Weight-loss drugs like Ozempic ...

More than one-third of websites selling their own versions implied the products were the same as the FDA-approved drugs.

The first study to assess how weight-loss drugs affect the whole of human health has discovered an "eye-opening" impact on ...

Over 2 million people were included in new research to test these drugs against 175 different health outcomes.

An observational study has uncovered a possible link between taking GLP-1s and increased risk of kidney, pancreas and gut ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.